Extendicare Inc (EXE) Fair Value & Analysis
Healthcare · CA · Market cap C$3.1B
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 5 days ago
Share price +8.9% over the past month.
Price vs Fair Value (12 months)
12‑month range C$11.62 – C$34.14 · fair‑value band C$10.39 – C$22.95 · the C$34.13 price screens above the C$16.04 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Extendicare Inc (EXE) currently trades at C$34.13, while our model-based Fair Value estimate is C$16.04 — implying the stock looks roughly 53.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Extendicare Inc generated revenue of C$1.8B at a net margin of 7.0%. Revenue grew 24.2% year over year. It earns a return on equity of 47.2%. The balance sheet holds a net cash position of C$6.3M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. It operates through the Long-term Care, Home Health Care, and Managed Services segments. The company offers long-term care services, such as accommodation and meals, and assistance with activities of daily living and continuing care to residents; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties and joint ventures. It provides its services under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network brands. The company was incorporated in 1968 and is based in Markham, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Extendicare Inc reported revenue of C$1.7B in FY2025 versus C$1.2B in FY2021, a compound +9.2%/yr. Reported net income was C$96.7M in FY2025, compounding +70.3%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Tenet Healthcare Corporation THC | $178.75 | $300.86 | +68% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Extendicare Inc (EXE) undervalued?
What is the fair value of EXE?
What is the quality score of EXE?
What is the revenue of Extendicare Inc (EXE)?
What is the net profit margin of EXE?
Does Extendicare Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.